Reactivities of a Prostanoid EP2 Agonist, Omidenepag, Are Useful for Distinguishing between 3D Spheroids of Human Orbital Fibroblasts without or with Graves’ Orbitopathy
Background. To obtain new insights into the activation of the thyroid-stimulating hormone (TSH) and insulin-like growth factor 1 (IGF-1) receptors in human orbital fibroblasts (n-HOFs), the effects of the prostanoid EP2 agonist, omidenepag (OMD), and a rho-associated coiled-coil-containing protein k...
Guardado en:
Autores principales: | Yosuke Ida, Hanae Ichioka, Masato Furuhashi, Fumihito Hikage, Megumi Watanabe, Araya Umetsu, Hiroshi Ohguro |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c153308afa234843a145a51e10e3f285 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori N, et al.
Publicado: (2021) -
Subconjunctival orbital fat prolapse and thyroid associated orbitopathy: a clinical association
por: Chatzistefanou KI, et al.
Publicado: (2017) -
Endoscopic Orbital Decompression for Graves’ Orbitopathy – A Vietnam Study
por: Pham TMH, et al.
Publicado: (2021) -
Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves’ orbitopathy and analysis on who requires additional therapy
por: Tsirouki T, et al.
Publicado: (2016) -
Evaluation of the association between subconjunctival orbital fat prolapse and thyroid-associated orbitopathy
por: Han SB
Publicado: (2017)